PENTAMIDINE ISETHIONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pentamidine Isethionate, and when can generic versions of Pentamidine Isethionate launch?
Pentamidine Isethionate is a drug marketed by Seton Pharms, X-gen Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Hospira, Watson Labs, and Xgen Pharms. and is included in eight NDAs.
The generic ingredient in PENTAMIDINE ISETHIONATE is pentamidine isethionate. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentamidine isethionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pentamidine Isethionate
A generic version of PENTAMIDINE ISETHIONATE was approved as pentamidine isethionate by SETON PHARMS on September 28th, 2017.
Summary for PENTAMIDINE ISETHIONATE
Recent Clinical Trials for PENTAMIDINE ISETHIONATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mayo Clinic | Phase 1 |
University of Louisville | Phase 1 |
Gyongyi Szabo | Phase 1 |
Pharmacology for PENTAMIDINE ISETHIONATE
Drug Class | Antiprotozoal |